Daiichi Sankyo, Eisai Pioneer OTC Entry Using APIs Of Major Drugs
This article was originally published in PharmAsia News
Executive Summary
Daiichi Sankyo and Eisai, acting with government backing, plan to develop over-the-counter versions of some of their major drugs